Form 8-K BIOGEN INC. For: May 03
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Leerink Modestly Positive on Biogen's (BIIB) Hemophilia Spin; Remains Cautious on Rest of Company
May 3, 2016 2:52 PM EDTLeerink affirms Biogen (Nasdaq: BIIB) with a Market Perform rating and $319 price target following news that the company is going to spin-off its hemophilia unit.
Analyst Geoffrey Porges commented: In a somewhat surprising move, Biogen announced today that it will spin off its hemophilia business into an... More
